> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dengvaxia Regulatory Review Period Determined
- URL: https://www.fdaweb.com/dengvaxia-regulatory-review-period-determined/
- Published: 2021-11-03T12:00:00.000Z
- Updated: 2026-09-14T17:21:19.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150504

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Sanofi’s Dengvaxia (dengue tetravalent vaccine, live), indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4\. The review period is 5,710 days, which includes 5,466 days that occurred during the testing phase and 244 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-24067.pdf?ref=fdaweb.com).